HEPCVAX - Unraveling hcv pathogenicity for the preclinical development of new therapeutic strategies (HEPCVAX) (LIFE QUALITY) (2002-09-01 - 2005-08-31) (»add to infobox)

Frank DAMEN, Hubert E. BLUM, Alain MERIEUX, Patrick SAUBOST, Veronique DEBISSCHOP, Dominique PELLA, Gilles BLOCK, Gerd Rudolf PAPE, Peter KLEIN, Giovanni GIRONE, Juerg REICHEN, Hermann FUNK, Domitien DEBOUZIE, Brigitte OLIVET, Pierre ESPINASSE

UNIVERSITEIT LEIDEN (NL331 - Agglomeratie Leiden en Bollenstreek) (Netherlands), ALBERT-LUDWIGS-UNIVERSITAET FREIBURG (DE131 - Freiburg im Breisgau, Stadtkreis) (Germany), BIOMERIEUX SA (FR716 - Rhône) (France), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR301 - Nord) (France), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR716 - Rhône) (France), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR716 - Rhône) (France), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR421 - Bas-Rhin) (France), LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE212 - München, Kreisfreie Stadt) (Germany), PEVION BIOTECH AG (CH021 - Bern) (Switzerland), UNIVERSITA DEGLI STUDI DI BARI (ITF42 - Bari) (Italy), UNIVERSITAET BERN (CH021 - Bern) (Switzerland), UNIVERSITAETSKLINIKUM HEIDELBERG (DE125 - Heidelberg, Stadtkreis) (Germany), UNIVERSITE CLAUDE BERNARD LYON 1 (FR716 - Rhône) (France), UNIVERSITE DE PARIS V 'RENÉ DESCARTES' (FR101 - Paris) (France), UNIVERSITY OF OXFORD (UK523 - Oxfordshire) (Great Britain)

The overall objectives of the HepCVax cluster is to identify viral and host mechanisms which are involved in(I) viral replication and particle formation, (ii) pathogen city and viral persistence and, based on the knowledge of virus properties as well as virus-host interactions and pathogenesis, (iii) to identify innovative antiviral and immunotherapeutic strategies capable of inducing a broad and sustained HCV specific cellular-mediated immune responses. All information emerging from the understanding of the HCV genome will be integrated in the first ever-European sequence database dedicated to Hepatitis C virus. The cluster will be subdivided in three component Networks. Whereas HepCVax-PARTIC will concentrate on the molecular and intracellular level of the virus-host interactions through the identification of factors involved in HCV-particles formation, HepCVax.IMPA TH will focus on the interaction between HCV and different arms of the innate and adaptive immune response. HepCVax-PRECLIN will exploit the expected discoveries made by Networks 1 and 2 to develop and test new immunotherapeutic strategies in vitro and in small animal models.

PERSONS (15/15)

RELATED NAVIGATION AREA(S) (3/3)